ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

5:00PM-5:50PM: Abstract Number: 0493

Automatic Joint Space Assessment in Hand Radiographs with Deep Learning Among Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes III: Major Comorbidities in RA (0489–0493)

5:00PM-5:50PM: Abstract Number: 0473

Characterization of DOCK8 as a Novel Gene Associated with Cytokine Storm Syndrome

Pediatric Rheumatology – Basic Science (0469–0473)

5:00PM-5:50PM: Abstract Number: 0468

Concerns and Health-Related Behaviors During the COVID-19 Pandemic in Patients with or Without Autoimmune Rheumatic Disease in a Large Physician Network

Patient Outcomes, Preferences, & Attitudes I: COVID-19 (0464–0468)

5:00PM-5:50PM: Abstract Number: 0466

Dosage Modification of Immunomodulatory Medications by Rheumatology Patients in New York City During the Peak of the COVID-19 Pandemic

Patient Outcomes, Preferences, & Attitudes I: COVID-19 (0464–0468)

5:00PM-5:50PM: Abstract Number: 0495

Epstein Barr Virus (EBV), an Etiologic Factor for Systemic Lupus Erythematosus (SLE), Interacts with SLE Risk Loci Through EBV-encoded Transcription Co-factors (co-TFs)

SLE – Etiology & Pathogenesis (0494–0498)

5:00PM-5:50PM: Abstract Number: 0498

Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE Pathogenesis

SLE – Etiology & Pathogenesis (0494–0498)

5:00PM-5:50PM: Abstract Number: 0490

Fine Specificity Anti-Citrullinated Protein Antibodies as Biomarkers for Prediction of Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease

RA – Diagnosis, Manifestations, & Outcomes III: Major Comorbidities in RA (0489–0493)

5:00PM-5:50PM: Abstract Number: 0494

Genetic-epigenetic Interaction and the Relationship Between DNA Methylation Patterns and Disease Activity in a Longitudinal Cohort of Lupus Patients

SLE – Etiology & Pathogenesis (0494–0498)

5:00PM-5:50PM: Abstract Number: 0500

Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Psoriatic Arthritis (0499–0503)

5:00PM-5:50PM: Abstract Number: 0469

IFNγ Is Essential for Alveolar Macrophage Driven Lung Inflammation in Macrophage Activation Syndrome

Pediatric Rheumatology – Basic Science (0469–0473)

5:00PM-5:50PM: Abstract Number: 0467

Incidence of COVID-19 in Patients Treated with Infliximab Compared to Patients Treated with Rituximab

Patient Outcomes, Preferences, & Attitudes I: COVID-19 (0464–0468)

5:00PM-5:50PM: Abstract Number: 0502

Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Psoriatic Arthritis (0499–0503)

5:00PM-5:50PM: Abstract Number: 0497

Interleukin-23 Acts Directly on Podocytes and Contributes to the Development of Glomerulonephritis

SLE – Etiology & Pathogenesis (0494–0498)

5:00PM-5:50PM: Abstract Number: 0492

Microbiota-induced Intestinal Barrier Dysfunction Initiates the Shuttling of Immune Cells from the Gut to the Joints

RA – Diagnosis, Manifestations, & Outcomes III: Major Comorbidities in RA (0489–0493)

5:00PM-5:50PM: Abstract Number: 0489

Prevalence, Incidence, and Cause-Specific Mortality of Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Older Patients with Rheumatoid Arthritis: A Nationwide Cohort Study

RA – Diagnosis, Manifestations, & Outcomes III: Major Comorbidities in RA (0489–0493)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].